Clinical Trial Update: Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

View source ↗

Summary

A clinical trial evaluating toxicity determinants and responses to azacitidine and venetoclax in acute myeloid leukemia. It is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Leukemia, Myeloid, Acute | Status: RECRUITING